Avoid common mistakes on your manuscript.
Correction to: Cancer Immunology, Immunotherapy https://doi.org/10.1007/s00262-022-03359-2
The article Real‑world multicentre cohort of first‑line pembrolizumab alone or in combination with platinum‑based chemotherapy in non‑small cell lung cancer PD‑L1 ≥ 50%, written by E. Pons‑Tostivint, P. Hulo, V. Guardiolle, L. Bodot, A. Rabeau, M. Porte, S. Hiret, P. Demontrond, H. Curcio, A. Boudoussier, R. Veillon, M. Mayenga, C. Dumenil, T. Chatellier, P. A. Gourraud, J. Mazieres, J. Bennouna, was originally published electronically on the publisher’s internet portal on 24 January 2023 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 8 February 2023 to © The Author(s) 2022 and this article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pons-Tostivint, E., Hulo, P., Guardiolle, V. et al. Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%. Cancer Immunol Immunother 72, 1891–1892 (2023). https://doi.org/10.1007/s00262-023-03405-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-023-03405-7